Symbols

GMAB

Genmab·NASDAQ

--(--)

GMAB fundamentals

GMAB Q4 2025 Earnings

Genmab (GMAB) released its earnings on Feb 17, 2026: revenue was 1.06B (YoY +18.22%), beat estimates; EPS was 0.4715 (YoY -44.59%), beat estimates.

Revenue / YoY

1.06B

+18.22%

EPS / YoY

0.4715

-44.59%

Report date

Feb 17, 2026

GMAB Earnings Call Summary for Q4,2025

Revenue Growth: 19% YoY to $3.7 billion, with proprietary medicines contributing 28% of total revenue.
Pipeline Catalysts: Up to 6 registrational readouts in 2026 for EPKINLY, Rina-S, and petosemtamab.
Commercial Momentum: EPKINLY sales up 17% to $468 million; TIVDAK expands into Europe with $164 million in sales.
Strategic Investments: $1.15 billion operating profit in 2026 to fund late-stage development and launches.
Pipeline Expansion: 3 IND filings for next-gen ADCs and bispecifics; Merus integration accelerates head and neck cancer trials.

Earnings

EPS

Revenue

Revenue & Expenses

GMAB has released its 2025 Q4 earnings report, with revenue of 1.06B, reflecting a YoY change of 14.63%, and net profit of 31.00M, showing a YoY change of -94.38%. The Sankey diagram below clearly presents GMAB's revenue sources and cost distribution.

Key Indicators

Genmab (GMAB) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Genmab (GMAB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Genmab (GMAB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Genmab (GMAB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown